GlassScriptPhysician profile
Leonid Reyfman
NPI 1659440394
$15,537.48
in general payments reported to CMS, 2019-2025
39 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $377 · 2021: $780 · 2022: $1,513 · 2023: $9,612 · 2024: $891 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $3,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $3,299.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Milestone Scientific INC. | $9,000.00 | 2023 | |
| Medtronic, INC. | $2,038.49 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbvie INC. | $742.42 | 2021-2025 | |
| Abbott Laboratories | $302.60 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $284.83 | 2022 | |
| Relievant Medsystems, INC. | $243.21 | 2022 | |
| Boston Scientific Corporation | $233.91 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $224.00 | 2020-2025 | Ztlido |
| Saluda Medical Americas, INC. | $223.23 | 2024-2025 | Evoke |
| Medtronic USA, INC. | $189.64 | 2019-2020 | |
| Globus Medical, INC. | $172.61 | 2025 | Senza |
| Nevro Corp. | $149.94 | 2019 | |
| Alkermes, INC. | $140.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.30 | 2020-2024 | Relistor |
| Aesculap, INC. | $128.63 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $124.63 | 2023 | Reactiv8 |
| Stimwave Technologies Incorporated | $123.71 | 2022 | |
| Eisai INC. | $110.01 | 2025 | |
| Biodelivery Sciences International, INC. | $90.81 | 2020-2021 | |
| Si-Bone, INC. | $87.17 | 2019 | |
| Pfizer INC. | $76.52 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $74.48 | 2024-2025 | |
| Horizon Therapeutics Plc | $74.06 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $55.81 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $48.69 | 2020-2021 | |
| Depuy Synthes Sales INC. | $44.78 | 2019-2024 | Orthovisc |
| Neuronetics, INC. | $44.45 | 2024 | Neurostar Tms Therapy System |
| Valinor Pharma, LLC | $42.35 | 2024 | Movantik |
| Pacira Therapeutics, INC. | $41.85 | 2019 | |
| Spinefrontier, INC. | $39.53 | 2020 | |
| Amgen INC. | $37.71 | 2019 | |
| Curonix LLC | $35.77 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Forte Bio-Pharma LLC | $29.89 | 2025 | Prolate, Tanlor, Nalocet |
| Almatica Pharma LLC | $28.57 | 2021 | |
| Epimed International, INC | $28.50 | 2019 | |
| Redhill Biopharma INC. | $22.37 | 2022 | |
| Lilly USA, LLC | $22.00 | 2022 | |
| Lundbeck LLC | $21.48 | 2025 | Vyepti |
| Indivior INC. | $20.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Reyfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.